The medical technology company HeartFlow is now valued at over $1 billion, the latest company to hit the category threshold for the most highly valued startups.
HeartFlow is expected to collect $150 million in a new fundraising round, according to a new regulatory filing in Delaware uncovered by PitchBook. At a price of about $25.33 per share, HeartFlow will have a valuation of $1.4 billion.
The company did not immediately respond to a request for comment. It last raised money at a $760 million valuation in May 2016, according to PitchBook.
HeartFlow, founded in 2010, sells a product to doctors to detect coronary artery disease.
Investors have included U.S. Venture Partners, GE Ventures and the venture fund of insurer Blue Cross Blue Shield. The new backers of this funding round are not immediately known.
This article originally appeared on Recode.net.